Analysis of anti-asthmatic drug patents published in China between 2004 and 2013

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 3, 2016, Pages 363-376

  Xie, Hua ^a,b   Zhang, Huiyun ^a   Cao, Ke ^a   He, Ping ^c   Dai, Hongliang ^a   He, Shaoheng ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^c Environmental Law Department   (United Kingdom)

Author keywords

Anti asthmatic drug; Beta2 adrenoceptor agonist; Chinese patent; Synthetic compound; Traditional Chinese medicine

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHAMOMILE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; HISTAMINE RELEASE INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE; PUMICE;

ALLIUM; ALLIUM MACROSTEMON; ANIMAL SHELL; APRICOT; ARTEMISIA VULGARIS; ASTER (GENUS); ASTER TATARICUS; ASTHMA; BLACKBERRY; BLACKBERRY LILY; CASSIA; CHINA; CHINESE MEDICINE; CHRISTIA VESPERTILIONIS; DANDELION; DRUG INDUSTRY; EXOCARPIUM; FERMENTED PINELLIA; FLOS FARFARAE; FOLIUM MORI; FOMES; FOMES OFFICINALIS AMES; GARDENIA; GLYCYRRHIZA; HERBA EPIMEDII; HUMAN; INDIGO NATURALIS; INFORMATION RETRIEVAL; INULA; LILY; MEDICINAL PLANT; PATENT; PERILLA; PEUCEDANUM PRAERUPTORUM; PINELLIA; PLANT LEAF; PLATYCODON; POLYGALA TENUIFOLIA; PORIA COCOS; RADIX PAEONIAE ALBA; RADIX STEMONAE; REVIEW; SCAPHIUM SCAPHIGERUM; SEMEN LEPIDII; SOPHORA FLAVESCENS; WESTERN MEDICINE; ANIMAL; DRUG DESIGN;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHINA; DRUG DESIGN; HUMANS; INTELLECTUAL PROPERTY; PATENTS AS TOPIC;

EID: 84959495274     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2016.1136289     Document Type: Review

References (58)

1. Baïz N, Annesi-Maesano I. Is the asthma epidemic still ascending? Clin Chest Med. 2012;33(3):419-429.
2. From the global strategy for asthma management and prevention. Global Initiative for Asthma (GINA); 2015 Available from: http://www.ginasthma.org/
3. Wechsler ME. Getting control of uncontrolled asthma. Am J Med. 2014;127(11):1049-1059.
4. Zhang S, Zeng X, Wei J, et al. Analysis of patents on antiallergic therapies issued in China from 1988 to 2008. Expert Opin Ther Pat. 2010;20(6):727-737.
5. Hao H, MA J, LI J, et al. Salmeterol preparation method. CN103420856A. 2013.
6. Bessa J, Dalmases BP, Marquillas OF. New derivatives of 6-(4-phenylbutoxy) hexylamine and process for producing salmeterol. CN1189446C. 2005.
7. Baker D, Bruce Mark. Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist. CN102724974A. 2012.
8. Lohse O, Monnier S, Jordine G. Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist. CN101511794A. 2009.
9. KOV MERLI VALERIANO MANTOVANI. Levalbuterol hydrochloride polymorph A. CN1934068A. 2007.
10. Chen Jianfeng, Liu Xiaolin, Xu Jing. Synthetic method for superfine sulfuric acid and salbutamol. CN1566076A. 2005.
11. Adam H, Daniel B, Chen Yan, et al. Diamide compounds having muscarinic receptor antagonist and ss2 adrenergic receptor agonist activity. CN102405218A. 2012.
12. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533:36-39.
13. STEFFEN SPECK, GEORG PIEPER. MIC. Carbamic acid esters with anticholinergic activity. CN1717408A. 2006.
14. Meissner P, Morschhae H. Novel anticholinergic agents that can be used as medicaments and method for the production thereof. CN1275962C. 2006.
15. JI Y-H, Husfeld C, Lange C, et al. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists. CN101616893A. 2009.
16. Baker D, Bruce M, Crater G, et al. Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist. CN102724974A. 2012.
17. Meade CJM. Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation. CN1829520A. 2006.
18. Pairet M, Meade M, John C, et al. Inhalation medicaments containing a novel anticholinesterase drug in conjunction with corticosteroids and betamimetic drugs. CN1688308A. 2005.
19. Jingwang XU. Modulators of muscarinic receptors. CN101573121A. 2009.
20. Bailey A, Mete A, Pairaudeau G, et al. New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder. CN101490003A. 2009.
21. Kristian N, Tolf B-R-R, Nicholas MK. Benzimidazolidinone derivatives as muscarinic agents. CN1561212A. 2005.
22. LUETTKE ROLD BANHOLZER MANFRED; Method for producing anticholinergic agent substitute bromide. CN1244581C. 2006.
23. LIU X. Method for preparing tiotropium bromide. CN101230063A. 2008.
24. Collingwood SP. Combinations of glycopyrrolate and beta2 adrenoceptor agonists. CN1953745A. 2007.
25. Xiangfu Y, Chongdong Z, Chensheng H, et al. Method for preparing 7-(2-hydroxypropyl) theophylline. CN102875554A. 2013.
26. Xiangfu-Y, Chongdong Z, Chensheng H, et al. 8-chlorotheophylline preparation method. CN103360394A. 2013.
27. Meissner R. 2-[1-phenyl-5-hydroxy or methoxy-4alphamethyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands. CN101528707A. 2009.
28. Cheng H, Hu X, Kevin DJ, et al. Tricyclic compounds and their use as glucocorticoid receptor modulators. CN101616896A. 2009.
29. Ding M, Hu X, Pei W, et al. Synthesis method for ciclesonide. CN101857627A. 2010.
30. Kai D, Fengjie G. Method for synthesizing key intermediate of fluticasone propionate. CN103193844A. 2013.
31. Weike S, Jiadi Z, Xiangjun S, et al. Synthesis method of key intermediate 17-beta-carboxylic acid derivative of fluticasone derivative. CN103073609A. 2013.
32. Hegi W, Bandla J. Preparation of furoic acid momisone. CN1149222C. 2004.
33. Dumitru C, Chan SMH, Turcanu V. Role of leukotriene receptor antagonists in the management of pediatric asthma: an update. Paediatr Drugs. 2012;14(5):317-330.
34. Alessandra B, Todd B, Zhidong C, et al. Oxadiazole inhibitors of leukotriene production. CN103261193A. 2013.
35. Laliberte S, Grimm Erich L, Gareau Y, et al. Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor, CN102627638A. 2012.
36. Bhupathy M, Bergan J. Process for the preparation of leukotriene antagonists. CN101081834A. 2007.
37. Yang L. Method for preparing zafirlukast important intermediate. CN101104601A. 2008.
38. Wang T, Yu Q, Yuan B, et al. Preparation method of Montelukast Sodium intermediate. CN102442947A. 2012.
39. Michael Woolven James AD. Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands. CN101501003A. 2009.
40. Wang T, Yu Q, Yuan B, et al. Preparation method of Montelukast Sodium intermediate. CN102442947A. 2012.
41. Choi-Sledeski YM, Nakyen C, Gregory Bernard P, et al. [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indol-3-yl]-methanone as an inhibitor of mast cell tryptase. CN102149705B. 2013.
42. BEIHAN DU BOIS DAISY JOE KERTE. Piperazine derivatives for use as CCR-3 receptor antagonists in the treatment of asthma.CN1321115C. 2007.
43. Ebel H, Frattini S, Giovannini R, et al. Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd. CN102256 963A. 2011.
44. Lebaut G, Manthew C, Kutetsche B N-substituted indole-3-acetaldehyde amide compound with anti-asthma, antiamaphylactic and immunosupression/immunoregulation action. CN100488948C. 2009.
45. Fanjing S. Traditional Chinese medicine composition for treating asthma. CN103463305A. 2013.
46. Yanning LI. Medicament for treating infantile asthma. CN103463537A. 2013.
47. Yipeng L. Traditional Chinese medicine composition for treating bronchial asthma and preparing method thereof. CN103417886A. 2013.
48. Liying S, Dayong Y. Golden camellia flavonoid glycoside as well as preparation method and application thereof. CN103951723A. 2014.
49. Sheng Y, Haibin L, Tingting L, et al. Application and preparation method of benzo alpha-pyrone compounds. CN103494806A. 2013.
50. Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ. 2014 24;349:g5517.
51. Sugihara N, Kanada S, Haida M, et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. Respir Med. 2010;104(11):1629-1637.
52. Wenzel SE, Wang L, Pirozzi G. Dupilumab in persistent asthma. N Engl J Med. 2013;369:1276.
53. Gauvreau GM, Boulet LP, Cockcroft DW, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008;177:952-958.
54. Beeh K-M, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013;131:866-874.
55. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294-1302.
56. Parulekar AD, Boomer JS, Patterson BM, et al. A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. Am J Respir Crit Care Med. 2013;187 (5):494-501.
57. Reber LL, Daubeuf F, Plantinga M, et al. A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol. 2012;188(7):3478-3487.
58. Xie H, Zhang H, Zhang S, et al. Analysis of antibiotic patents issued in China from 1992 to 2011. Expert Opin Ther Pat. 2012;22(10):1205-1232.